On november 1, 2022, genmark was advised of unexpected negative results for staphylococcus aureus on the eplex bcid-gp panel tested on (b)(6) 2022, where the eplex bcid-gp panel detected an unspeciated staphylococcus result.Culture performed on (b)(6) 2022 identified staphylococcus aureus.On november 3, 2022, during communication related to the investigation, genmark was advised that the patient associated with the result was deceased on (b)(6) 2022.Genmark was advised the eplex bcid-gp results were not reported to the physician; however, the customer declined to comment further on the impact of the eplex bcid-gp results.On november 29, 2022, the customer indicated that they would not provide any further information on the matter.Data was analyzed per internal procedures and confirmed robust internal controls were generated for the eplex bcid-gp run suggesting the consumable performed as expected.Review of the eplex gp panel test run information for this sample shows robust signal for staphylococcus and low level signal that did not breach threshold for staphylococcus aureus.This suggests the test performed as described in the package insert, where it indicates, the eplex bcid-gp panel staphylococcus result is based on four assays: the species-specific staphylococcus aureus, staphylococcus epidermidis and staphylococcus lugdunensis assays and a broad staphylococcus assay.The broad staphylococcus assay will detect each of the species targeted by the species-specific assays, but its primary purpose is to detect other staphylococcus species.If all four assays are negative, the staphylococcus result will be ¿not detected¿.If any of the four assays is positive, the staphylococcus result will be ¿detected¿.If only the staphylococcus assay is positive, an unspeciated staphylococcus has been detected.
|
Analysis: internal review of qc release data for affected lot 91292929 confirms the consumable lot successfully met the established qc release specifications.Review of the eplex bcid-gp panel test run information demonstrates that the internal controls were valid.No run malfunction was observed and the eplex instrument (serial # (b)(4)) was working within design specifications.Conclusion: while a discrepant result was reported by the customer, no quality and/or performance issues have been identified for the affected eplex bcid-gp panel lot.Genmark¿s investigation suggests the panel functioned as intended, and in accordance with the genus and group target results interpretation described in the package insert.The eplex bcid-gp panel was appropriately used according to the product's intended use, which describes the assay as an aid in the diagnosis of bloodstream infection when used in conjunction with other clinical information.The results from the eplex bcid-gp panel are intended to be interpreted in conjunction with gram stain results and should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.
|